How Pfizer’s Sutent and Xalkori Have Performed

Sutent revenue

In the first nine months of this year, Pfizer’s (PFE) Sutent sales fell 2% YoY (year-over-year) to $785.0 million from $805.0 million. Sutent operations declined ~5% YoY. US Sutent sales fell ~6% YoY to $262.0 million from $277.0 million, and international Sutent sales fell 1% YoY to $524.0 million from $527.0 million.

In the third quarter, Sutent revenue fell ~10% YoY to $248.0 million. US and international Sutent revenue fell ~7% and ~11% YoY to $80.0 million and $168.0 million, respectively.

How Pfizer’s Sutent and Xalkori Have Performed

Xalkori revenue

In the first nine months of this year, Pfizer’s Xalkori sales fell ~6% to $417.0 million from $442.0 million, and Xalkori operations declined ~9% YoY. US and international Xalkori revenue fell ~31% and ~10% YoY, respectively, to $118.0 million and $299.0 million.

In the third quarter, Xalkori revenue fell ~13% YoY to $127.0 million. US and international Xalkori sales fell ~31% and ~4% YoY to $34.0 million and $93.0 million, respectively. Xalkori competes with Roche’s (RHHBY) Alecensa, Novartis’s (NVS) Zykadia, and Takeda Pharmaceutical’s (TKPYY) Alunbrig. In the first nine months of this year, Roche’s Alecensa revenue grew 79% YoY to 437.0 million Swiss francs.